ofloxacin has been researched along with Bronchitis, Chronic in 16 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Bronchitis, Chronic: A subcategory of CHRONIC OBSTRUCTIVE PULMONARY DISEASE. The disease is characterized by hypersecretion of mucus accompanied by a chronic (more than 3 months in 2 consecutive years) productive cough. Infectious agents are a major cause of chronic bronchitis.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The purpose of this study was to determine the intrapulmonary profile of high-dose (750 mg) levofloxacin in patients during an acute exacerbation of chronic bronchitis (AECB)." | 9.16 | Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750 mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis. ( Baughman, RP; Nicolau, DP; Sutherland, C; Winget, D, 2012) |
| "We compared the efficacy and safety of moxifloxacin and levofloxacin for the treatment of patients with acute exacerbations of chronic bronchitis (AECB) using a prospective, randomized, double blind, parallel-group clinical trial design." | 9.12 | Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort. ( Amábile-Cuevas, CF; Ariza, H; Caballero, A; García-Calderón, A; Hernández-Oliva, G; Jardim, JR; Urueta-Robledo, J; Vivar-Orozco, R, 2006) |
| "To compare the safety and efficacy of oral azithromycin and levofloxacin in the treatment of outpatients with acute bacterial exacerbations of chronic bronchitis (ABECB)." | 9.10 | Efficacy and safety of azithromycin vs levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis. ( Amsden, GW; Baird, IM; Simon, S; Treadway, G, 2003) |
| "A randomized, double-blind, multicentre study was conducted in adult patients with acute exacerbation of chronic bronchitis (AECB), to compare the efficacy of a 5-day course of levofloxacin 500 mg once daily, with the standard 7-day regimen at the same dose." | 9.09 | Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis. ( Burley, CJ; Masterton, RG, 2001) |
| "Clinical and bacteriological efficacies of levofloxacin versus clarithromycin and azithromycin were evaluated in 41 patients with chronic bronchitis infectious exacerbation in the Respiratory-Recovery Centre of Polyclinic No." | 7.74 | [Levofloxacin and macrolides in chronic bronchitis exacerbation: comparative analysis of the treatment efficacy and nonrelapsing periods]. ( Dubrovskaia, NV; Dvoretskiĭ, LI; Filimonova, OIu; Grudinina, SA; Iakovlev, SV; Sidorenko, SV, 2007) |
| " The oral bioavailability of levofloxacin is over 99%, enabling simple switching from intravenous to oral therapy during treatment." | 6.43 | Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin. ( Cantón, R; Graninger, W; Lode, H; Milkovich, G, 2006) |
| "Levofloxacin was measured using a high-performance liquid chromatographic tandem mass spectrometric (HPLC/MS/MS) technique." | 5.34 | Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease. ( Conte, JE; Golden, JA; Little, E; McIver, M; Zurlinden, E, 2007) |
| " The purpose of this study was to determine the intrapulmonary profile of high-dose (750 mg) levofloxacin in patients during an acute exacerbation of chronic bronchitis (AECB)." | 5.16 | Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750 mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis. ( Baughman, RP; Nicolau, DP; Sutherland, C; Winget, D, 2012) |
| "To evaluate the clinical and bacterial efficacies and the safety of antofloxacin hydrochloride tablets in the treatment of acute exacerbations of chronic bronchitis (AECB) and acute pyelonephritis (AP)." | 5.14 | A phase II study of antofloxacin hydrochloride, a novel fluoroquinolone, for the treatment of acute bacterial infections. ( Bai, C; Huang, W; Mei, C; Wang, J; Xiao, Y; Xiu, Q; Xu, N; Zheng, Q, 2010) |
| "We compared the efficacy and safety of moxifloxacin and levofloxacin for the treatment of patients with acute exacerbations of chronic bronchitis (AECB) using a prospective, randomized, double blind, parallel-group clinical trial design." | 5.12 | Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort. ( Amábile-Cuevas, CF; Ariza, H; Caballero, A; García-Calderón, A; Hernández-Oliva, G; Jardim, JR; Urueta-Robledo, J; Vivar-Orozco, R, 2006) |
| "To compare the safety and efficacy of oral azithromycin and levofloxacin in the treatment of outpatients with acute bacterial exacerbations of chronic bronchitis (ABECB)." | 5.10 | Efficacy and safety of azithromycin vs levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis. ( Amsden, GW; Baird, IM; Simon, S; Treadway, G, 2003) |
| "A randomized, double-blind, multicentre study was conducted in adult patients with acute exacerbation of chronic bronchitis (AECB), to compare the efficacy of a 5-day course of levofloxacin 500 mg once daily, with the standard 7-day regimen at the same dose." | 5.09 | Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis. ( Burley, CJ; Masterton, RG, 2001) |
| "Clinical and bacteriological efficacies of levofloxacin versus clarithromycin and azithromycin were evaluated in 41 patients with chronic bronchitis infectious exacerbation in the Respiratory-Recovery Centre of Polyclinic No." | 3.74 | [Levofloxacin and macrolides in chronic bronchitis exacerbation: comparative analysis of the treatment efficacy and nonrelapsing periods]. ( Dubrovskaia, NV; Dvoretskiĭ, LI; Filimonova, OIu; Grudinina, SA; Iakovlev, SV; Sidorenko, SV, 2007) |
| "This study aimed to explore the pharmacokinetic features of levofloxacin (LVFX) in Chinese patients with infections and to confirm oral LVFX 500 mg once daily as an optimal treatment regimen based on pharmacokinetic-pharmacodynamic (PK-PD) analysis." | 2.74 | Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China. ( Cao, GY; Huang, JA; Liu, YB; Shi, YG; Si, B; Sun, SH; Wu, XJ; Xia, QM; Xiao, ZK; Xu, JF; Zhang, J; Zhang, YY, 2009) |
| " The oral bioavailability of levofloxacin is over 99%, enabling simple switching from intravenous to oral therapy during treatment." | 2.43 | Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin. ( Cantón, R; Graninger, W; Lode, H; Milkovich, G, 2006) |
| " Sequential therapy is easily administered due to its high oral bioavailability, and the dosing schedule can be a convenient once-daily dose." | 2.41 | Optimal treatment strategies for acute exacerbations of chronic bronchitis: high-risk patients. ( Norrby, SR, 2001) |
| "Levofloxacin was measured using a high-performance liquid chromatographic tandem mass spectrometric (HPLC/MS/MS) technique." | 1.34 | Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease. ( Conte, JE; Golden, JA; Little, E; McIver, M; Zurlinden, E, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (87.50) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dvoretskiĭ, LI | 1 |
| Dubrovskaia, NV | 1 |
| Grudinina, SA | 1 |
| Filimonova, OIu | 1 |
| Sidorenko, SV | 1 |
| Iakovlev, SV | 2 |
| Zhang, J | 1 |
| Xu, JF | 1 |
| Liu, YB | 1 |
| Xiao, ZK | 1 |
| Huang, JA | 1 |
| Si, B | 1 |
| Sun, SH | 1 |
| Xia, QM | 1 |
| Wu, XJ | 1 |
| Cao, GY | 1 |
| Shi, YG | 1 |
| Zhang, YY | 1 |
| Wang, J | 1 |
| Xiao, Y | 1 |
| Huang, W | 1 |
| Xu, N | 1 |
| Bai, C | 1 |
| Xiu, Q | 1 |
| Mei, C | 1 |
| Zheng, Q | 1 |
| Nicolau, DP | 1 |
| Sutherland, C | 1 |
| Winget, D | 1 |
| Baughman, RP | 1 |
| Weiss, LR | 1 |
| Iakovlev, VP | 1 |
| Amsden, GW | 1 |
| Baird, IM | 1 |
| Simon, S | 1 |
| Treadway, G | 1 |
| Martinez, FJ | 1 |
| Grossman, RF | 1 |
| Zadeikis, N | 1 |
| Fisher, AC | 1 |
| Walker, K | 1 |
| Ambruzs, ME | 1 |
| Tennenberg, AM | 1 |
| Urueta-Robledo, J | 1 |
| Ariza, H | 1 |
| Jardim, JR | 1 |
| Caballero, A | 1 |
| García-Calderón, A | 1 |
| Amábile-Cuevas, CF | 1 |
| Hernández-Oliva, G | 1 |
| Vivar-Orozco, R | 1 |
| Cantón, R | 1 |
| Lode, H | 1 |
| Graninger, W | 1 |
| Milkovich, G | 1 |
| Kahn, JB | 1 |
| Khashab, M | 1 |
| Ambruzs, M | 1 |
| Petitpretz, P | 1 |
| Choné, C | 1 |
| Trémolières, F | 1 |
| Conte, JE | 1 |
| Golden, JA | 1 |
| McIver, M | 1 |
| Little, E | 1 |
| Zurlinden, E | 1 |
| Norrby, SR | 1 |
| Masterton, RG | 1 |
| Burley, CJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00042718] | Phase 3 | 659 participants (Actual) | Interventional | 2001-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for ofloxacin and Bronchitis, Chronic
| Article | Year |
|---|---|
[Levofloxacin in the treatment of respiratory infections].
Topics: Acute Disease; Anti-Infective Agents; Bronchitis, Chronic; Clinical Trials as Topic; Drug Resistance | 2002 |
Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin.
Topics: Anti-Bacterial Agents; Bronchitis, Chronic; Community-Acquired Infections; Fluoroquinolones; Humans; | 2006 |
Optimal treatment strategies for acute exacerbations of chronic bronchitis: high-risk patients.
Topics: Anti-Infective Agents; Bronchitis, Chronic; Diagnosis, Differential; Humans; Levofloxacin; Ofloxacin | 2001 |
10 trials available for ofloxacin and Bronchitis, Chronic
| Article | Year |
|---|---|
Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Bacterial Agents; Bronchitis, Chronic; China; Co | 2009 |
A phase II study of antofloxacin hydrochloride, a novel fluoroquinolone, for the treatment of acute bacterial infections.
Topics: Acute Disease; Adult; Aged; Anti-Bacterial Agents; Bronchitis, Chronic; Demography; Double-Blind Met | 2010 |
Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750 mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Area Under Curve; | 2012 |
Open-label, randomized comparison of the efficacy and tolerability of clarithromycin, levofloxacin, and cefuroxime axetil in the treatment of adults with acute bacterial exacerbations of chronic bronchitis.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Bronchit | 2002 |
Efficacy and safety of azithromycin vs levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis.
Topics: Acute Disease; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bacterial In | 2003 |
Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg.
Topics: Administration, Oral; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Amoxicillin-Potassium Clavul | 2005 |
Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Argentina; Aza Compounds; Brazil; Bronchitis, Chronic; | 2006 |
Study entry microbiology in patients with acute bacterial exacerbation of chronic bronchitis in a clinical trial stratifying by disease severity.
Topics: Acute Disease; Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Azithromy | 2007 |
Levofloxacin 500 mg once daily versus cefuroxime 250 mg twice daily in patients with acute exacerbations of chronic obstructive bronchitis: clinical efficacy and exacerbation-free interval.
Topics: Aged; Bronchitis, Chronic; Cefuroxime; Female; Heart Failure; Humans; Levofloxacin; Male; Middle Age | 2007 |
Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agen | 2001 |
3 other studies available for ofloxacin and Bronchitis, Chronic
| Article | Year |
|---|---|
[Levofloxacin and macrolides in chronic bronchitis exacerbation: comparative analysis of the treatment efficacy and nonrelapsing periods].
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Bronchitis, Chronic; Clarithrom | 2007 |
[Equally whether the child's lung or chronically inflamed bronchi. Acute bacterial infections have to be terminated fast].
Topics: Adult; Age Factors; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; B | 2004 |
Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease.
Topics: Adult; Aged; Area Under Curve; Blood Chemical Analysis; Bronchitis, Chronic; Bronchoalveolar Lavage | 2007 |